1. Home
  2. RELI vs QLGN Comparison

RELI vs QLGN Comparison

Compare RELI & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RELI
  • QLGN
  • Stock Information
  • Founded
  • RELI 2013
  • QLGN 1996
  • Country
  • RELI United States
  • QLGN United States
  • Employees
  • RELI N/A
  • QLGN N/A
  • Industry
  • RELI Specialty Insurers
  • QLGN Biotechnology: Pharmaceutical Preparations
  • Sector
  • RELI Finance
  • QLGN Health Care
  • Exchange
  • RELI Nasdaq
  • QLGN Nasdaq
  • Market Cap
  • RELI 3.3M
  • QLGN 3.2M
  • IPO Year
  • RELI N/A
  • QLGN N/A
  • Fundamental
  • Price
  • RELI $2.14
  • QLGN $4.07
  • Analyst Decision
  • RELI Strong Buy
  • QLGN
  • Analyst Count
  • RELI 1
  • QLGN 0
  • Target Price
  • RELI $119.00
  • QLGN N/A
  • AVG Volume (30 Days)
  • RELI 5.6M
  • QLGN 20.7K
  • Earning Date
  • RELI 11-07-2024
  • QLGN 11-14-2024
  • Dividend Yield
  • RELI N/A
  • QLGN N/A
  • EPS Growth
  • RELI N/A
  • QLGN N/A
  • EPS
  • RELI N/A
  • QLGN N/A
  • Revenue
  • RELI $14,078,473.00
  • QLGN N/A
  • Revenue This Year
  • RELI N/A
  • QLGN N/A
  • Revenue Next Year
  • RELI N/A
  • QLGN N/A
  • P/E Ratio
  • RELI N/A
  • QLGN N/A
  • Revenue Growth
  • RELI 4.71
  • QLGN N/A
  • 52 Week Low
  • RELI $1.18
  • QLGN $3.34
  • 52 Week High
  • RELI $18.53
  • QLGN $29.45
  • Technical
  • Relative Strength Index (RSI)
  • RELI 49.98
  • QLGN 45.00
  • Support Level
  • RELI $1.73
  • QLGN $3.95
  • Resistance Level
  • RELI $2.50
  • QLGN $4.21
  • Average True Range (ATR)
  • RELI 0.41
  • QLGN 0.27
  • MACD
  • RELI -0.07
  • QLGN 0.00
  • Stochastic Oscillator
  • RELI 27.33
  • QLGN 22.08

About RELI Reliance Global Group Inc.

Reliance Global Group Inc operates as a holding company with diversified interests in the insurance market, as well as other related sectors. The company focuses on growing by pursuing an acquisition strategy, initially and primarily focused on wholesale and retail insurance agencies. Its primary strategy is to identify specific risks to reward arbitrage opportunities and develop these on a national platform, thereby increasing revenues and returns, and then identify and acquire undervalued wholesale and retail insurance agencies with operations in growing or underserved segments, expand and optimize their operations, and achieve asset value appreciation while generating interim cash flows. The company generates revenue in the form of commissions.

About QLGN Qualigen Therapeutics Inc.

Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.

Share on Social Networks: